136 related articles for article (PubMed ID: 6403139)
1. Serum long acting thyroid stimulator protector in pregnancy complicated by Graves' disease.
Hardisty CA; Munro DS
Br Med J (Clin Res Ed); 1983 Mar; 286(6369):934-5. PubMed ID: 6403139
[TBL] [Abstract][Full Text] [Related]
2. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
Hardisty CA; Hanford L; Munro DS
Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
[TBL] [Abstract][Full Text] [Related]
3. The effect of radioiodine and antithyroid drugs on serum long acting thyroid stimulator protector (IATS-P). A three year prospective study.
Hardisty CA; Fowles A; Munro DS
Clin Endocrinol (Oxf); 1984 May; 20(5):597-605. PubMed ID: 6547647
[TBL] [Abstract][Full Text] [Related]
4. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
Hardisty CA; Hanford L; Humphries H; Munro DS
Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
[TBL] [Abstract][Full Text] [Related]
5. Long-acting thyroid stimulator and related factors.
Kendall-Taylor P; Dirmikis SM; Munro DS
Proc R Soc Med; 1975 Apr; 68(4):252-3. PubMed ID: 1242809
[No Abstract] [Full Text] [Related]
6. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
Hardisty CA; Fowles A; Munro DS
J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of neonatal Graves' disease.
McKenzie JM; Zakarija M
J Endocrinol Invest; 1978 Apr; 1(2):183-9. PubMed ID: 385703
[No Abstract] [Full Text] [Related]
8. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
[TBL] [Abstract][Full Text] [Related]
9. Neonatal thyrotoxicosis.
Robards GJ; Davis JR
Med J Aust; 1973 Sep; 2(9):432-4. PubMed ID: 4800423
[No Abstract] [Full Text] [Related]
10. The pathogenesis of Graves' disease.
Gossage AA; Munro DS
Clin Endocrinol Metab; 1985 May; 14(2):299-330. PubMed ID: 2866051
[TBL] [Abstract][Full Text] [Related]
11. The role of thyroid stimulating immunoglobulins of Graves's disease in neonatal thyrotoxicosis.
Munro DS; Dirmikis SM; Humphries H; Smith T; Broadhead GD
Br J Obstet Gynaecol; 1978 Nov; 85(11):837-43. PubMed ID: 581471
[No Abstract] [Full Text] [Related]
12. Thyroid stimulating immunoglobulin in Graves' disease.
Luttrell BM; Hales IB
Aust N Z J Med; 1981 Jun; 11(3):293-8. PubMed ID: 6170289
[TBL] [Abstract][Full Text] [Related]
13. Placental transmission of thyroid-stimulating immunoglobulins.
Dirmikis SM; Munro DS
Br Med J; 1975 Jun; 2(5972):665-6. PubMed ID: 1173561
[TBL] [Abstract][Full Text] [Related]
14. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin G inhibitor of thyroid-stimulating antibody is a cause of delay in the onset of neonatal Graves' disease.
Zakarija M; McKenzie JM; Munro DS
J Clin Invest; 1983 Oct; 72(4):1352-6. PubMed ID: 6138363
[TBL] [Abstract][Full Text] [Related]
16. Neonatal thyrotoxicosis with long acting thyroid stimulator-protector.
O'Hearlihy C
Ir Med J; 1977 Mar; 70(4):124-5. PubMed ID: 576864
[No Abstract] [Full Text] [Related]
17. Thyroid function parameters and TSH-receptor antibodies in healthy subjects and Graves' disease patients: a sequential study before, during and after pregnancy.
González-Jiménez A; Fernández-Soto ML; Escobar-Jiménez F; Glinoer D; Navarrete L
Thyroidology; 1993 Apr; 5(1):13-20. PubMed ID: 7508738
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for neonatal thyroid dysfunction in pregnancies complicated by Graves' disease.
Uenaka M; Tanimura K; Tairaku S; Morioka I; Ebina Y; Yamada H
Eur J Obstet Gynecol Reprod Biol; 2014 Jun; 177():89-93. PubMed ID: 24726178
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism.
Zakarija M; McKenzie JM
J Clin Endocrinol Metab; 1983 Nov; 57(5):1036-40. PubMed ID: 6137493
[TBL] [Abstract][Full Text] [Related]
20. Immunological aspects of Graves' disease and importance of thyroid stimulating immunoglobulins.
Bech K
Acta Endocrinol Suppl (Copenh); 1983; 254():3-38. PubMed ID: 6191508
[No Abstract] [Full Text] [Related]
[Next] [New Search]
